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Background: This is a subgroup analysis of Korean patients from a phase 3 clinical trial investigating the efficacy and safety of ip-
ragliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin. 
Methods: This multicenter, placebo-controlled, double-blind, parallel-group study was carried out between November 2011 and 
January 2013. Patients entered a 2-week placebo pretreatment period, followed by a 24-week treatment period with either ipra-
gliflozin (50 mg/day) or placebo, while continuing metformin. Efficacy outcomes (glycosylated hemoglobin [HbA1c], fasting 
plasma glucose [FPG], and body weight) and safety outcomes (treatment-emergent adverse events [TEAEs]) were measured and 
compared between the two treatment groups for patients enrolled in all 18 study sites in Korea.
Results: Eighty-two Korean patients received ipragliflozin (n=43) or placebo (n=39) during the study period. Mean changes in 
HbA1c levels from baseline to the end of treatment were –0.97% in the ipragliflozin group and –0.31% in the placebo group, with 
an adjusted between-group difference of –0.60% (P<0.001). Compared to placebo, FPG and body weight also decreased signifi-
cantly (both P<0.001) from baseline after treatment in the ipragliflozin group, with between-group differences of –21.4 mg/dL 
and –1.53 kg, respectively. Decreased weight was the most common TEAE in the ipragliflozin group (7.0%); there were no reports 
of genital and urinary tract infection.
Conclusion: Ipragliflozin treatment in addition to metformin led to significant improvement in glycemic outcomes and reduc-
tion in body weight in Korean patients with type 2 diabetes mellitus, compared with metformin treatment alone; the safety profile 
was comparable in both groups.
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INTRODUCTION
The incidence of diabetes has increased by more than 6-fold 
over the past 40 years in Korea [1]. Recent estimates by the Ko-
rean Diabetes Association indicate that type 2 diabetes mellitus 
affects approximately 2.7 million adults (aged 30 years or old-
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er), placing the current prevalence of type 2 diabetes mellitus 
at 8.0% [2]. With rising body mass index (BMI) and increasing 
incidence of metabolic syndrome in Korea [2,3], the preva-
lence of diabetes and its associated morbidity and mortality is 
expected to continue on an upward trend. 
The Korean treatment guideline for diabetes recommends 
lifestyle modifications (diet and exercise) and an oral hypogly-
cemic agent (typically metformin) as the first-line therapy for 
the management of hyperglycemia in type 2 diabetes mellitus 
[4]. If optimal glycemic control cannot be attained with first-
line therapy, other classes of glucose-lowering agents that tar-
get insulin secretion such as sulfonylureas and dipeptidyl pep-
tidase-4 inhibitors are commonly added to improve glycemic 
control [4]. However, the efficacy of these agents may eventu-
ally diminish as β-cell function deteriorates and insulin secre-
tory capacity reduces with disease progression [5]. Because 
impaired insulin secretion and increased insulin resistance are 
the main pathological features of type 2 diabetes mellitus [5], 
and Asian patients have the propensity to develop diabetes 
with greater insulin resistance and reduced insulin secretion 
compared with white patients [6,7], combination therapy with 
other classes of agents that lower blood glucose in an insulin-
independent manner will eventually be necessary to maintain 
glycemic control, especially in Asian patients with diabetes.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a 
new class of oral hypoglycemic agents that lower blood glucose 
levels via mechanisms independent of insulin. As SGLT2 is the 
main glucose transporter that facilitates renal glucose reab-
sorption [8], SGLT2 inhibitors block the reabsorption of glu-
cose in the kidney and increase urinary glucose excretion; 
thereby, lowering blood glucose levels. The mechanism of 
SGLT2 inhibitors in lowering blood glucose is insulin-inde-
pendent, and therefore patients with type 2 diabetes mellitus 
are likely to benefit from SGLT2 inhibitor therapy regardless of 
the level of pancreatic β-cell function or the degree of insulin 
resistance. 
The 2015 update to the position statement of the American 
Diabetes Association [9] and the 2015 Korean treatment 
guidelines for diabetes [4] now include SGLT2 inhibitors as a 
possible option for dual therapy with metformin if target gly-
cosylated hemoglobin (HbA1c) levels are not reached within 3 
months. Metformin and SGLT2 inhibitor dual therapy may 
also be initiated from the start if a patient has a HbA1c level 
greater than 7.5% at diagnosis [4].
Although the efficacy and safety of ipragliflozin (a SGLT2 
inhibitor) in combination with metformin have been demon-
strated in previous trials conducted in Asian patients with type 
2 diabetes mellitus [10,11], the effects in Korean patients, spe-
cifically, remains to be 
evaluated. This article presents a subgroup analysis of a 
phase 3, multicenter, placebo-controlled, double blind, paral-
lel-group study [11], with the objective of examining the effi-
cacy and safety of ipragliflozin in combination with metformin 
in Korean patients with type 2 diabetes mellitus. 
METHODS
This was a phase 3, multicenter, placebo-controlled, double-
blind, parallel-group comparative study. The Institutional Re-
view Board at each study site reviewed and approved the study 
protocol, case report forms, and documents used for informed 
consent. The study was conducted in accordance with Good 
Clinical Practice, the International Conference on Harmoniza-
tion Technical Requirements for Registration of Pharmaceuti-
cals for Human Use, as well as applicable local laws and regula-
tions. All patients provided written informed consent before 
study enrollment. The study design was described in a previ-
ous report [11]. This subgroup analysis only included the Ko-
rean patients, which comprised patients recruited from all 18 
sites in Korea between November 2011 and January 2013.
Study population
Inclusion criteria were as follows: aged ≥20 years; diagnosed 
with type 2 diabetes mellitus ≥12 weeks before enrollment; 
underwent a stable diet and exercise regimen for ≥8 weeks; 
treated with metformin at a stable dose of ≥1,500 mg/day (or 
≥1,000 mg/day if higher doses were not administered due to 
safety concerns); recorded as having baseline HbA1c between 
7% to 10% and BMI between 20.0 and 45.0 kg/m2. Briefly, ex-
clusion criteria included patients with type 1 diabetes mellitus, 
patients who received insulin within 12 weeks of enrollment, 
patients with proliferative diabetic retinopathy and renal dis-
ease, patients who were pregnant or lactating, and patients 
who were women of childbearing potential and not willing to 
use appropriate contraception during the study. A full list of 
exclusion criteria was previously reported [11]. This study was 
registered at ClinicalTrials.gov (identifier NCT01505426).
Study design and treatments
The total duration of the study was 30 weeks and included a 
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single-blind 2-week placebo pretreatment period (visit 1), fol-
lowed by a 24-week double-blind treatment period (visits 2 to 
9), and a 4-week follow-up period (visit 10). Patients who were 
receiving hypoglycemic agents other than metformin entered a 
washout period of at least 8 weeks prior to visit 1. Inclusion 
and exclusion criteria were assessed for each patient at visit 1, 
and eligible patients entered a 2-week placebo pretreatment 
period. At visit 2 (week 0), all eligible patients were randomly 
assigned to receive either ipragliflozin (50 mg/day) or a place-
bo as an additional treatment to metformin. Randomization 
was conducted in a 1:1 ratio by patient stratification for study 
site and HbA1c level at visit 1 (<8.0% or ≥8.0%) using a com-
puter-generated randomization schedule. After the random-
ization procedure, the patients returned during the 24-week 
treatment period for visit 3 (week 2), visit 4 (week 4), and visits 
5 to 9 scheduled every 4 weeks until the end of treatment (visit 
9, week 24). The follow-up visit (visit 10) was scheduled 4 
weeks after the end of treatment. The study drugs used were 
indistinguishable in terms of packaging and appearance. As-
signment of study drug was masked to all patients, investiga-
tors, and study sponsor. Treatment codes were only released 
after the study database was locked.
With the exception of the prescribed study drug and metfor-
min, use of any drugs that affect plasma glucose levels was pro-
hibited during the study period. Continuous systemic admin-
istration of corticosteroids, immunosuppressants, or loop di-
uretics for chronic diseases were also prohibited, although top-
ical or temporary use was permitted. Changes to diet and exer-
cise therapy were also prohibited until the end of study period.
Study assessments
All clinical laboratory assessments were carried out at a central 
laboratory (Mitsubishi Chemical Medience Corporation, To-
kyo, Japan) using routine methods. The primary efficacy out-
come, HbA1c, was measured every 4 weeks during the treat-
ment period. Secondary efficacy parameters included fasting 
plasma glucose (FPG; measured at each visit), body weight 
(measured at each visit), waist circumference (measured at vis-
its 2 and 9), and fasting serum insulin (FSI; measured at visits 
2, 6, and 9). Values measured at visit 2 (week 0 of treatment pe-
riod) were used as the baseline for all efficacy variables. 
Safety assessments included adverse events, vital signs, and 
laboratory tests (hematology, serum chemistry, and urinalysis; 
visits 2 to 10). Adverse events that were observed after the first 
administration of the study drug were defined as treatment-
emergent adverse events (TEAEs). Serious TEAEs were any 
TEAEs for which the patient outcome was one of the follow-
ing: death, threat to life, persistent or significant disability or 
incapacity, congenital anomaly or birth defect, required inpa-
tient hospitalization or prolonged hospitalization and other 
medically important interventions to prevent permanent im-
pairment or damage. A 3-grade scale was used to assess the se-
verity of TEAEs: mild-resulted in no disruption of normal daily 
activities; moderate-affected normal daily activities; and severe-
resulted in an inability to perform daily activities. To maintain 
blinding, measurements of urinary glucose were not permitted 
throughout the entire study period, unless deemed necessary 
due to safety concerns.
Statistical analyses
The sample sizes for each region where the study was conduct-
ed (Korea and Taiwan) were estimated based on the results of a 
dose finding study conducted in Japan [12]. It was estimated 
that at least 34 evaluable patients per treatment group would 
be required to detect differences in the change from baseline in 
HbA1c levels between the treatment groups with 90% power at 
the 5% significance level in each country.
The full analysis set (FAS) consisted of all patients who re-
ceived at least 1 dose of the study drug, and in whom at least 1 
efficacy variable was measured after administration of the 
study drug during the treatment period. The per protocol set 
(PPS) was a subset of the FAS and further satisfied the follow-
ing criteria: fulfilled eligibility criteria, received the study drug 
and metformin for at least 56 days during the treatment peri-
od, achieved ≥80% compliance with the study drug and met-
formin during the treatment period, did not use prohibited 
concomitant medication, and did not have any clinically sig-
nificant protocol deviations. The safety analysis set (SAF) con-
sisted of all patients who received at least one dose of the study 
drug during the treatment period. 
Primary and secondary efficacy outcomes were assessed in 
the FAS and PPS (sensitivity analyses), while safety outcomes 
were assessed in the SAF. For calculation of changes from base-
line to the end of treatment, missing values at the end of treat-
ment were derived using the last observation carried forward 
method. The changes in primary and secondary outcomes 
from baseline to the end of treatment were compared between 
the treatment groups using analysis of covariance with the re-
spective baseline value as a covariate and treatment group as a 
fixed effect. Demographics, baseline characteristics, and safety 
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outcomes were summarized by treatment group. Continuous 
variables were reported as mean±standard deviation, while 
categorical data were expressed as number (%) in each treat-
ment group. Differences between the two treatment groups 
were analyzed using two-sample t-test for continuous variables 
or Fisher exact test for categorical variables. Homeostatic mod-
el assessment of insulin resistance (HOMA-IR) and homeo-
static model assessment of β-cell function (HOMA-β) were 
calculated using the following formulas: HOMA-IR=[FSI 
(µU/mL)×FPG (mg/dL)]/405; HOMA-β=[360×FSI (µU/mL)]/
[FPG (mg/dL)–63]. The software SAS version 9.1.3 (SAS Insti-
tute Inc., Cary, NC, USA) was used for all statistical analyses 
and a P value less than 0.05 was considered to be statistically 
significant. 
RESULTS
Patient disposition and baseline characteristics
A total of 238 patients entered the study from 30 sites in Korea 
and Taiwan [11]. Of these, 121 (50.8%) were enrolled from Ko-
rea. Fig. 1 shows patient disposition during the study period. A 
total of 38 patients discontinued the study before randomiza-
tion, and 83 patients were randomized at visit 2 (43 to ipra-
gliflozin and 40 to placebo). One patient discontinued before 
starting treatment, leaving 43 who received ipragliflozin and 
39 who received placebo during the treatment period. These 
patients constituted the FAS and SAF. Among them, 67 pa-
tients (ipragliflozin 36, placebo 31) completed treatment, of 
whom 35 and 31 from the ipragliflozin and placebo groups, re-
spectively, were included in the PPS.
Patient demographics and baseline characteristics for the 
FAS are presented in Table 1. Age, BMI, and waist circumfer-
ence of both groups were comparable at baseline. There were 
some slight imbalances between the two groups in terms of 
gender distribution and proportion of patients with an esti-
mated glomerular filtration rate of <90 mL/min/1.73 m2, al-
though these differences did not reach statistical significance. 
Glycemic variables such as HbA1c, FPG, and FSI were similar 
at baseline, and there were no significant differences between 
the two groups in duration of diabetes and the proportion of 
patients with complications. The mean±standard deviation 
duration of exposure to study drug was 148.0±49.49 and 
121 Provided informed consent
117 Received placebo run-in
83 Randomized
40 Prescribed placebo
39 Received placebo
31 Completed treatment
43 Prescribed ipragliflozin
43 Received ipragliflozin
36 Completed treatment
4 Discontinued before placebo run-in
2 Ineligible 
2 Withdrew consent
34 Discontinued before randomizaion
32 Ineligible 
  1 Withdrew consent
  1 Other reasons
1  Discontinued before starting 
treatment
1 Withdrew consent
8  Discontinued after starting  
treatment
1 Ineligible 
2 Withdrew consent
5 Protocol violation
7  Discontinued after starting 
treatment
4 Ineligible 
2 Withdrew consent
1 Protocol violation
Fig. 1. Patient disposition.
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147.3±47.81 days in the ipragliflozin and placebo groups, re-
spectively. Mean compliance rates were above 95% in both 
groups.
Efficacy
Primary efficacy outcome
Fig. 2A shows the change in mean HbA1c levels from baseline 
to the end of treatment period in both groups. Mean HbA1c 
decreased over time to a greater extent in the ipragliflozin 
group than in the placebo group. Mean±standard deviation 
change of HbA1c from baseline to the end of treatment was 
–0.97%±0.811% and –0.31%±0.790% in the ipragliflozin and 
placebo groups, respectively, with a between-group adjusted 
mean difference of –0.60% (95% confidence interval [CI], 
–0.873% to –0.337%; P<0.001). The difference between the ip-
ragliflozin and placebo groups was maintained in subgroup 
analyses, after stratifying patients by gender and baseline 
HbA1c (data not shown). The proportion of patients who 
achieved the target HbA1c level of <7.0% increased from 16.3% 
(7/43) at baseline to 75.6% (31/41) at the end of treatment in 
the ipragliflozin group, and from 7.7% (3/39) to 41.0% (16/39) 
in the placebo group. The proportion of patients who achieved 
the target HbA1c level of <6.5% increased from 0.0% (0/43) at 
baseline to 29.3% (12/41) at the end of treatment in the ipra-
gliflozin group, and from 0.0% (0/39) to 7.7% (3/39) in the pla-
cebo group. HbA1c results with the PPS population were con-
sistent with the FAS (data not shown).
Secondary efficacy outcomes
The time-courses of the changes in mean FPG in both treat-
ment groups are shown in Fig. 2B. Mean FPG decreased over 
time in the ipragliflozin group but increased slightly in the pla-
cebo group. The mean±standard deviation changes in FPG 
from baseline to the end of treatment were –24.9±40.39 mg/dL 
in the ipragliflozin group and 2.9±36.88 mg/dL in the placebo 
group, with a between-group adjusted mean difference of 
–21.4 mg/dL (95% CI, –32.03 to –10.83 mg/dL; P<0.001).
Body weight decreased from baseline to the end of treatment 
Table 1. The patients’ demographics and baseline characteristics (full analysis set)
Characteristic Placebo Ipragliflozin P value
Number 39 43
Sex 0.191a
   Male 15 (38.5) 23 (53.5)
   Female 24 (61.5) 20 (46.5)
Age, yr 56.5±9.79 55.7±11.25 0.752b
Age ≥65 yr 8 (20.5) 10 (23.3) 0.796a
Body weight, kg 68.96±12.242 68.12±13.817 0.774b
BMI, kg/m2 26.15±3.466 25.50±3.829 0.430b
BMI ≥25 kg/m2 21 (53.8) 20 (46.5) 0.659a
Waist circumference at start of treatment, cm 87.23±9.274 85.23±8.600 0.313b
HbA1c at start of treatment (NGSP), % 7.62±0.782 7.67±0.853 0.767b
FPG at start of treatment, mg/dL 138.2±32.09 146.1±42.92 0.354b
FSI at start of treatment, µIU/mL 8.06±7.929 7.11±5.656 0.535b
Duration of diabetes, mo 86.5±57.04 94.0±80.83 0.628b
Complications, yes 39 (100.0) 42 (97.7) 1.000a
Treatment with drugs other than metformin ≤12 weeks before visit 1, yes 1 (2.6) 2 (4.7) 1.000a
eGFR at start of treatment, mL/min/1.73 m2 128.74±46.036 128.06±39.933 0.943b
eGFR at start of treatment <90 mL/min/1.73 m2 1 (2.6) 5 (11.6) 0.205a
Values are presented as number (%) or mean±standard deviation. Data shown are for Visit 1 unless otherwise specified. 
BMI, body mass index; HbA1c, glycated hemoglobin; NGSP, National Glycohemoglobin Standardization Program; FPG, fasting plasma glu-
cose; FSI, fasting serum insulin; eGFR, estimated glomerular filtration rate.
aFisher exact test, bTwo-sample t-test.
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in both groups (Table 2). The mean±standard deviation 
changes in body weight were –2.66±2.20 kg in the ipragliflozin 
group and –1.13±1.90 kg in the placebo group. The between-
group adjusted mean difference in the changes in body weight 
from baseline to the end of treatment was –1.53 kg (95% CI, 
–2.44 to –0.61 kg; P=0.001). By the end of treatment, 32.6% 
(14/43) and 12.8% (5/39) of patients in the ipragliflozin and 
placebo groups, respectively, had a weight reduction of ≥5%.
HOMA-IR decreased in the ipragliflozin group (change, 
–0.34±1.79) and increased in the placebo group (change, 
0.41±1.78) from baseline to the end of treatment. However, 
the between-group adjusted mean difference of –0.75 (95% CI, 
–1.59 to 0.09; P=0.079) was not significant (Table 2). Similarly, 
HOMA-β increased in the ipragliflozin group (change, 6.24± 
36.68) and decreased in the placebo group (change, –1.37± 
77.07), but the between-group adjusted mean difference of 
2.88 (95% CI, –20.58 to 26.34; P=0.807) was not significant 
(Table 2). The changes in waist circumference and FSI from 
baseline to the end of treatment were comparable between 
both treatment groups (Table 2). Results of the secondary out-
comes with the PPS population were consistent with the FAS 
(data not shown).
Safety
Clinical and laboratory parameters
The changes in clinical and laboratory parameters from base-
Fig. 2. Time-courses of (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG) measurements. Values are 
mean±standard deviation. CI, confidence interval; NGSP, National Glycohemoglobin Standardization Program.
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line to the end of treatment in the SAF population are present-
ed in Table 3. At the end of the treatment period, systolic and 
diastolic blood pressures decreased in the ipragliflozin group 
(change in systolic/diastolic blood pressure: –9.6±14.72/–5.9± 
10.23 mm Hg) but not in the placebo group (change, 2.5± 
12.98/0.5±8.33 mm Hg; systolic blood pressure, P<0.001; dia-
stolic blood pressure, P=0.003). Plasma triglyceride levels de-
creased significantly in the ipragliflozin group but increased in 
the placebo group (change, –29.2±77.49 mg/dL vs. 11.3±98.60 
mg/dL; P=0.041). High density lipoprotein cholesterol (HDL-
C) levels improved significantly with ipragliflozin treatment 
compared to placebo group (change, 3.9±6.62 mg/dL vs. 0.4± 
6.02 mg/dL; P=0.014). Although mean low density lipoprotein 
cholesterol (LDL-C) levels decreased with ipragliflozin treat-
ment (change, –2.4±29.67 mg/dL) and increased with placebo 
(change, 7.2±23.89 mg/dL) from baseline to the end of treat-
ment, the difference did not reach statistical significance 
(P=0.114).
Treatment-emergent adverse events
The incidence of TEAEs in the SAF population are summarized 
in Table 4. TEAEs were experienced by 44.2% of patients in the 
ipragliflozin group and 43.6% in the placebo group. All TEAEs 
were either mild or moderate in severity. The incidences of seri-
ous TEAEs were 0.0% in the ipragliflozin group and 7.7% in the 
placebo group. Drug-related TEAEs occurred in 14.0% and 
15.4% of patients in the ipragliflozin and placebo group, respec-
tively. The most common TEAE in the ipragliflozin group was 
decreased weight; however, fatigue, nasopharyngitis, osteoar-
thritis, dysuria, and nocturia were more commonly reported in 
the placebo group. There were no reports of TEAEs related to 
hypoglycemia, urinary tract infection, genital infection, or pol-
Table 2. Changes in secondary efficacy variables from baseline to end of treatment (full analysis set)
Variable
Placebo Ipragliflozin Adjusted mean difference 
(95% CI) P value
a
Mean±SD Number Mean±SD Number
HOMA-IR 0.41±1.78 35 –0.34±1.79 38 –0.75 (–1.59 to 0.09) 0.079
HOMA-β –1.37±77.07 35 6.24±36.68 38 2.88 (–20.58 to 26.34) 0.807
Body weight, kg –1.13±1.90 39 –2.66±2.20 43 –1.53 (–2.44 to –0.61) 0.001
Waist circumference, cm –0.90±2.68 36 –1.23±2.43 39 –0.26 (–1.45 to 0.92) 0.661
FSI, µIU/mL 1.14±4.41 37 0.07±4.63 39 –0.90 (–2.93 to 1.12) 0.376
SD, standard deviation; CI, confidence interval; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model 
assessment of β-cell function; FSI, fasting serum insulin.
aAnalysis of covariance model including baseline value as a covariate. 
Table 3. Changes in clinical and laboratory parameters from baseline to end of treatment (safety analysis set)
Variable Placebo (n=39) Ipragliflozin (n=43) P valuea
SBP, mm Hg 2.5±12.98 –9.6±14.72 <0.001
DBP, mm Hg 0.5±8.33 –5.9±10.23 0.003
Pulse rate, /min –0.6±9.24 –2.1±8.16 0.429
eGFR, mL/min/1.73 m2 –7.62±32.34 –3.39±30.62 0.545
Total cholesterol, mg/dL 10.5±24.88 0.2±25.99 0.072
HDL-C, mg/dL 0.4±6.02 3.9±6.62 0.014
LDL-C, mg/dL 7.2±23.89 –2.4±29.67 0.114
Triglycerides, mg/dL 11.3±98.60 –29.2±77.49 0.041
Free fatty acids, mEq/L –0.036±0.205 –0.020±0.212 0.723
Values are presented as mean±standard deviation.
SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein choles-
terol; LDL-C, low density lipoprotein cholesterol.
aTwo-sample t-test. 
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lakiuria in the ipragliflozin group. Polyuria occurred during the 
treatment period in only one patient (2.3%), who was in the ip-
ragliflozin group.
Renal function, hematology, electrolytes, and liver function
Table 5 summarizes the changes in variables related to renal 
function, hematology, fluid and electrolyte balance, and liver 
function from baseline to the end of treatment in the SAF pop-
ulation. The changes in laboratory variables were mostly com-
parable between groups, with the exception of slightly greater 
increases in hematology parameters (red blood cell count, he-
moglobin, and hematocrit), and some fluid and electrolyte bal-
ance variables (magnesium, phosphorus, urine osmolality, 
urine potassium: creatinine ratio, and urine phosphorus: cre-
atinine ratio) in the ipragliflozin group than in the placebo 
group. These changes in hematology and electrolyte parame-
ters were not clinically significant and/or were within the nor-
mal range. Changes in variables related to renal function and 
liver function were not significantly different between the two 
treatment groups. 
DISCUSSION
In the present subgroup analysis of Korean patients with type 2 
diabetes mellitus inadequately controlled with metformin, ad-
dition of ipragliflozin to metformin therapy led to significant 
improvements in glycemic control (HbA1c and FPG) and re-
ductions in body weight compared to placebo. Improvements 
in clinical and laboratory parameters were also observed in the 
ipragliflozin group, with significantly lower blood pressure, 
decreased plasma triglycerides, increased HDL-C levels, and a 
tendency towards improved HOMA-IR after 24 weeks of treat-
ment compared to the placebo group. The safety profile of ip-
ragliflozin in terms of TEAEs and drug-related TEAEs was 
comparable to placebo, with only decreased weight being more 
common in patients given ipragliflozin compared to those giv-
en placebo.
The findings in this subgroup analysis are largely consistent 
with the main study comprising both Korean and Taiwanese 
patients with type 2 diabetes mellitus [11]. These findings are 
also consistent with the results from recent clinical trials of ip-
ragliflozin conducted in Western and Asian patients, where fa-
vorable changes in HbA1c, FPG, body weight, blood pressure, 
and triglyceride levels were reported regardless of ethnic group 
[10,12-15]. Both weight loss and reduction in blood pressure 
appear to represent a class effect of SGLT2 inhibitors [16,17]. 
The observed improvements in lipid profile and tendency to-
wards improvement in HOMA-IR may be a secondary effect 
of weight loss and reduced blood glucose. However, although 
many studies with SGLT2 inhibitors reported an increase in 
LDL-C levels [18-21], it is encouraging to note a slight decrease 
in mean LDL-C levels in Korean patients given ipragliflozin in 
the present study. 
At the same BMI, Koreans tend to be more insulin resistant 
compared to whites [22]. In the present study, we observed slight 
Table 4. Treatment-emergent adverse events (safety analysis 
set)
Variable Placebo Ipragliflozin
Number 39 43
No. of TEAEsa 38 37
Incidence of TEAEsb 17 (43.6) 19 (44.2)
   TEAEs by severityc
      Mild 12 (30.8) 17 (39.5)
      Moderate 5 (12.8) 2 (4.7)
      Severe 0 0 
   Serious TEAEs 3 (7.7) 0 
   TEAEs leading to study discontinuation 0 0 
No. of drug-related TEAEsa 9 10
Incidence of drug-related TEAEsb 6 (15.4) 6 (14.0)
   Drug-related TEAEs by severityc
      Mild 5 (12.8) 6 (14.0)
      Moderate 1 (2.6) 0 
      Severe 0 0 
   Serious drug-related TEAEs 0 0 
   Drug-related TEAEs leading to study
      discontinuation
0 0 
TEAEs in ≥5% of patients in either group
   Fatigue 2 (5.1) 1 (2.3)
   Nasopharyngitis 2 (5.1) 0 
   Weight decreased 0 3 (7.0)
   Osteoarthritis 2 (5.1) 0 
   Dysuria 2 (5.1) 1 (2.3)
   Nocturia 2 (5.1) 0 
Values are presented as number (%).
TEAE, treatment-emergent adverse event. 
aTotal number of events, where patients may have experienced two or 
more events, bPatients presenting with two or more TEAEs were 
counted only once, cThe most severe TEAE was counted if the patient 
presented with two or more TEAEs with varying severity.
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improvements in insulin sensitivity (measured by HOMA-IR) 
and β-cell function (measured by HOMA-β) with ipragliflozin 
treatment compared to placebo. However, these changes in 
HOMA-IR and HOMA-β did not reach statistical significance, 
this was probably due to the small sample size of the Korean 
subgroup. In the ILLUMINATE (ipragliflozin in combination 
with metformin for the treatment of Japanese patients with 
type 2 diabetes) study where Japanese patients were treated 
with ipragliflozin and metformin in a similar manner to the 
current study, significant improvements in insulin sensitivity 
Table 5. Change in hematology and other laboratory variables from baseline to end of treatment (safety analysis set)
Variable Placebo (n=39) Ipragliflozin (n=43) P valuea
Renal function
   BUN, mg/dL 1.1±3.97 2.9±4.56 0.072
   Cr, mg/dL 0.034±0.095 0.026±0.115 0.725
   BUN:Cr ratio 1.06±11.50 3.83±7.76 0.200
Hematology
   RBC count, ×104/µL –7.7±18.71 17.2±18.48 <0.001
   Hemoglobin, g/dL –0.26±0.75 0.42±0.58 <0.001
   Hematocrit, % –0.40±1.98 2.00±1.76 <0.001
Fluid and electrolyte balance
   Na, mEq/L –0.2±2.07 0.1±2.24 0.573
   K, mEq/L 0.06±0.41 0.15±0.33 0.259
   Cl, mEq/L –1.1±2.96 –0.3±2.92 0.251
   Ca, mg/dL –0.25±0.30 –0.25±0.46 0.980
   Mg, mg/dL 0.07±0.15 0.17±0.22 0.015
   P, mg/dL –0.07±0.47 0.19±0.45 0.013
   Urine NAG/Cr ratio, U/g Cr 0.42±5.93 1.83±6.53 0.312
   Urine albumin/Cr ratio, mg/g Cr 2.74±24.64 –10.93±58.92 0.182
   Urine osmolality, mOsm/L –41.9±223.54 58.5±219.58 0.043
   Urine Na/Cr ratio, mEq/g Cr 22.9±93.67 33.6±100.77 0.623
   Urine K/Cr ratio, mEq/g Cr 11.86±39.80 31.09±38.28 0.029
   Urine Cl/Cr ratio, mEq/g Cr 10.1±108.21 24.3±108.57 0.555
   Urine Ca/Cr ratio, mg/g Cr 11.04±73.00 29.34±93.79 0.331
   Urine Mg/Cr ratio, mg/g Cr 3.15±35.65 16.60±32.50 0.078
   Urine P/Cr ratio, mg/g Cr 55.66±291.31 277.89±315.43 0.001
Liver function
   AST, U/L –3.1±10.56 –3.9±7.89 0.704
   ALT, U/L –3.5±17.40 –8.7±17.75 0.192
   Total bilirubin, mg/dL 0.00±0.22 0.00±0.18 0.962
   Direct bilirubin, mg/dL 0.00±0.13 0.01±0.10 0.643
   LDH, U/L –5.4±28.36 –5.5±35.75 0.986
   ALP, U/L –4.2±29.01 –7.4±29.74 0.617
   γ-GTP, U/L –1.4±14.62 –8.1±18.40 0.073
Values are presented as mean±standard deviation.
BUN, blood urea nitrogen; Cr, creatinine; RBC, red blood cell; NAG, β-N-acetyl-D-glucosaminidase; AST, aspartate transaminase; ALT, alanine 
transaminase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; γ-GTP, γ-glutamyl transpeptidase.
aTwo-sample t-test.
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were reported [10]. The mean changes in HOMA-IR in the ip-
ragliflozin and placebo groups in the ILLUMINATE study were 
–1.04 and –0.08 respectively, corresponding to an adjusted be-
tween-group difference of –0.81 (95% CI, –1.156 to –0.460; 
P<0.001) [10]. In the present study, the adjusted between-
group difference for HOMA-IR (–0.75; 95% CI, –1.59 to 0.09; 
P=0.079) was almost comparable to that of the ILLUMINATE 
study. Other studies of SGLT2 inhibitors in Asian patients also 
reported that treatment for 24 weeks resulted in significant im-
provements in insulin sensitivity and β-cell function [20,23]. 
Considering that insulin resistance is strongly associated with 
diabetes in Koreans, and that increasing HOMA-IR had a larg-
er negative impact on FPG in Koreans compared to other non-
Asian populations [22], the beneficial effects of ipragliflozin on 
insulin sensitivity may be clinically important in the pathogen-
esis of type 2 diabetes mellitus in Korean patients.
Similar to the overall study population and the ILLUMI-
NATE study [10,11], we observed a slight increase in red blood 
cell count and hematocrit in Korean patients given ipra-
gliflozin treatment. These findings were expected due to the 
mechanism of ipragliflozin which results in an increase in 
urine output or water loss. On follow-up visits, these hemato-
logical variables returned to normal. In light of these data, it is 
important to advise patients to be adequately hydrated when 
on ipragliflozin treatment. Although we also found significant 
increases in urinary magnesium and phosphorous in the ipra-
gliflozin group, the clinical relevance of these changes remains 
to be determined. Glucosuria associated with SGLT2 inhibi-
tors typically increases the risk of urinary tract and genital in-
fections [24]. However, it is noteworthy that there were no re-
ports of urinary tract infections and genital infections in pa-
tients given ipragliflozin in the present study. The absence of 
such side effects may potentially enhance treatment satisfac-
tion and compliance with ipragliflozin.
Limitations of the study include the short duration of treat-
ment and relatively low mean HbA1c levels at baseline [11]. By 
nature of the subgroup analysis design, data interpretation may 
be limited by the small sample size. Nevertheless, the focus on 
Korean patients is a key strength of the analysis as this is the 
first report demonstrating the efficacy and safety of ipra-
gliflozin in combination with metformin in Korean patients 
with type 2 diabetes mellitus.
In conclusion, ipragliflozin added to metformin treatment 
led to significant improvements in glycemic outcomes and sev-
eral clinical parameters including body weight, lipid profile, 
and blood pressure in Korean patients with type 2 diabetes 
mellitus. There were no unexpected adverse events, and the 
safety profile of ipragliflozin was not markedly different from 
that of the placebo. Our data demonstrate the efficacy and 
safety of ipragliflozin in Korean patients with type 2 diabetes 
mellitus inadequately controlled with metformin alone. 
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